vedolizumab   Click here for help

GtoPdb Ligand ID: 7437

Synonyms: Entyvio® | LDP-02 | LDP02 | MLN-0002 | MLN-002 | MLN002
Approved drug Immunopharmacology Ligand
vedolizumab is an approved drug (FDA and EMA (2014))
Compound class: Antibody
Comment: Vedolizumab is a gut-selective monoclonal antibody that acts as an integrin antagonist by binding to α4β7 integrins on the surface of gastrointestinal-homing T lymphocytes.

Biosimilars:
NameTrade nameCompanyClinical PhaseIndications
PB016 n/aPolpharma Biologics/Fresenius KabiPhase 3moderate-severe active ulcerative colitis and Crohn's disease
Click here for help
References
1. Ponath PD, Ringler DJ, ST, Newman W, Saldanha J, Bendig MM. (2006)
Humanized immunoglobulin reactive with α4β7 integrin.
Patent number: US7147851 B1. Assignee: Millennium Pharmaceuticals, Inc.. Priority date: 15/08/1996. Publication date: 12/12/2006.
2. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. (2009)
The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
J Pharmacol Exp Ther, 330 (3): 864-75. [PMID:19509315]